PhD Scientific Days 2025

Poster Session II. - G: Pharmaceutical Sciences and Health Technologies

Establishing Value Judgement Thresholds for Health Technologies in Oman: A Consensus-Based Voting Approach

Előadó neve

Al Rashdi Said Wani, MSc

Neptun code

RH8AU7

Előadó munkahelye

Ministry of health, Muscat, Oman & Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary

Előadó telefonszáma

+36 70 585 8018

Előadó e-mail címe

said.rashdi@phd.semmelweis.hu

Az előadás címe

Establishing Value Judgement Thresholds for Health Technologies in Oman: A Consensus-Based Voting Approach

Szerző(k) neve és munkahelye

Al Rashdi Said Wani MSc^1,2,3

1: Ministry of health- Muscat – Oman
2: Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary
3: Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary

Bemutatás módja

Poszter

Szekció

Poster Session II. - G: Pharmaceutical Sciences and Health Technologies

Language of the presentation

English

Preferred session

Pharmaceutical Sciences and Health Technologies

Összefoglaló szövege

Background While Oman’s healthcare system is advancing, establishing cost-effectiveness thresholds (CETs) is crucial for guiding policymakers about the value of health technologies.
Objective This study aimed to develop CET’s for Oman that align with international standards while also considering the nation’s healthcare priorities and economic context.
Methods A combination approaches was used. key findings of a recently conducted systematic review were presented at a multistakeholder workshop in March 2024 in Muscat. Participants from various departments of the Ministry of Health such as providers, strategic planning, healthcare payers, and representatives from the university medical city were present at the workshop. In the workshop, the participants were asked to vote on the design of the CET framework, including baseline thresholds, multipliers pertaining to priority of the health system in Oman, rarity of the disease, and relative health gain, and what should be the actual values.
Results 20 respondents supported adopting a multiple-threshold system linked to Oman’s economic status, using the gross domestic product (GDP) per capita as the baseline. Participants endorsed three different threshold multipliers to reflect health policy priorities. A continuous multiplier ranging from 1 to 3, based on incremental relative QALY gain, was selected to favor technologies with significant health benefits. Additionally, a fixed multiplier of two was chosen for both orphan drugs and healthcare priority such as cancer treatment.
Conclusions In Oman, the incremental cost per QALY gained should not exceed 1x GDP per capita for new health technologies offering minimal benefit in common diseases. However, thresholds may increase up to 12x GDP per capita for curative treatments in rare cancers. It is recommended that CET values be reviewed and updated within three years, based on initial implementation experience.

University

Semmelweis University

Supervisor

Prof. Zoltán Kaló

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies before complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

8805

Start

18:18

End

18:24